MedTrace Logo

A Study of Single and Multiple Oral Doses of TollB-001

NCT06103773 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2023-10-27

No results posted yet for this study

Summary

The primary objective is to evaluate the safety and tolerability of TollB-001 following the administration of single or multiple oral doses in healthy adult subjects

Conditions

Interventions

DRUG

TollB-001 tablets

TollB-001 treatment

DRUG

TollB-001 placebo

TollB-001 Placebo

Sponsors & Collaborators

  • Toll Biotech Co. Ltd. (Beijing)

    lead INDUSTRY

Principal Investigators

  • wen he · Chengdu Fifth People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-28
Primary Completion
2024-06-09
Completion
2024-06-09

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06103773 on ClinicalTrials.gov